KOE:102940

Kolon Life Science Inc. · KOE · Basic Materials · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:28 UTC

Last close

n/aKRW

Market data

6.3xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
11.9%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-13.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

Safety is the furthest below its sector's middle: 0.19 against 0.59 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.33x

-0.74x

1.01x

1.14x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.33x
Its own average over 7 years, 157.15B.
Profit-0.74x
Its own average over 7 years, -33.39B.
Free cash flow1.01x
Its own average over 7 years, -27.83B.
Debt1.14x
Its own average over 7 years, 90.94B.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at -0.74 times.

Sales is 1.33 times its own 7-year average; Profit is -0.74 times its own 7-year average; Free cash flow is 1.01 times its own 7-year average; Debt is 1.14 times its own 7-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 7-year average1.33
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 7-year average-0.74
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 7-year average1.01
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 7-year average1.14
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW